摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2,6-bis(trifluoromethyl)-4-oxo-dihydrobenzopyran-3-carboxylate | 215124-12-2

中文名称
——
中文别名
——
英文名称
ethyl 2,6-bis(trifluoromethyl)-4-oxo-dihydrobenzopyran-3-carboxylate
英文别名
Ethyl 4-oxo-2,6-bis(trifluoromethyl)-2,3-dihydrochromene-3-carboxylate
ethyl 2,6-bis(trifluoromethyl)-4-oxo-dihydrobenzopyran-3-carboxylate化学式
CAS
215124-12-2
化学式
C14H10F6O4
mdl
——
分子量
356.221
InChiKey
GNBJDLQEUVOJDU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    52.6
  • 氢给体数:
    0
  • 氢受体数:
    10

反应信息

  • 作为反应物:
    描述:
    ethyl 2,6-bis(trifluoromethyl)-4-oxo-dihydrobenzopyran-3-carboxylate 在 sodium tetrahydroborate 作用下, 以 四氢呋喃乙醇 为溶剂, 反应 1.0h, 以87%的产率得到
    参考文献:
    名称:
    The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates
    摘要:
    In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data. The challenge of a surprisingly long half-life (t(1/2) = 360 h) of the first clinical candidate 1 and human t(1/2) had been difficult to predict based on allometric scaling for this class of highly ppb compounds. We used a microdose strategy which led to the discovery of clinical agents 18c-(S), 29b-(S), and 34b-(S) with human half-life of 57, 13, and 11 h. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.07.059
  • 作为产物:
    描述:
    ethyl 2,6-bis(trifluoromethyl)-4-oxo-4H-1-benzopyran-3-carboxylate盐酸 、 sodium tetrahydroborate 作用下, 以 四氢呋喃乙醇 为溶剂, 以87%的产率得到ethyl 2,6-bis(trifluoromethyl)-4-oxo-dihydrobenzopyran-3-carboxylate
    参考文献:
    名称:
    Substituted benzopyran analogs for the treatment of inflammation
    摘要:
    描述了一类苯并吡喃、苯并硫吡喃、二氢喹啉、二氢萘和其类似物,用于治疗环氧化酶-2介导的疾病。特别感兴趣的化合物由Formula I'定义,其中X、A.sup.1、A.sup.2、A.sup.3、A.sup.4、R、R"、R.sup.1和R.sup.2如规范中所述。
    公开号:
    US06077850A1
点击查看最新优质反应信息

文献信息

  • Substituted benzopyran analogs for the treatment of inflammation
    申请人:G.D. Searle & Co.
    公开号:US06077850A1
    公开(公告)日:2000-06-20
    A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I'wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.
    描述了一类苯并吡喃、苯并硫吡喃、二氢喹啉、二氢萘和其类似物,用于治疗环氧化酶-2介导的疾病。特别感兴趣的化合物由Formula I'定义,其中X、A.sup.1、A.sup.2、A.sup.3、A.sup.4、R、R"、R.sup.1和R.sup.2如规范中所述。
  • Substituted benzopyran derivatives for the treatment of inflammation
    申请人:G.D. Searle & Co.
    公开号:US06034256A1
    公开(公告)日:2000-03-07
    A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I' ##STR1## wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.
    所描述的苯并吡喃类衍生物用于治疗环氧合酶-2介导的疾病。特别感兴趣的化合物由式I'定义,其中X、A.sup.1、A.sup.2、A.sup.3、A.sup.4、R、R"、R.sup.1和R.sup.2如规范中描述。
  • Substituted bezopyran derivatives for the treatment of inflammation
    申请人:G.D. Searle & Co.
    公开号:US20040038977A1
    公开(公告)日:2004-02-26
    A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I′ 1 wherein X, A 1 , A 2 , A 3 , A 4 , R, R″, R 1 and R 2 are as described in the specification.
    本文介绍了一类苯并吡喃、苯并噻吩、二氢喹啉、二氢萘和其类似物,用于治疗环氧合酶-2介导的疾病。特别感兴趣的化合物由公式I'1定义,其中X、A1、A2、A3、A4、R、R″、R1和R2如规范中所述。
  • SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION
    申请人:G.D. SEARLE & CO.
    公开号:EP0977748B1
    公开(公告)日:2003-03-26
  • ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    申请人:Pharmacia Corporation
    公开号:EP1414526A2
    公开(公告)日:2004-05-06
查看更多